FINWIRES · TerminalLIVE
FINWIRES

NextNav Seen as Potential Acquisition Target Due to Sub-GHz Spectrum, Oppenheimer Says

By

NextNav's (NN) re-banding proposal, if approved, would give it control over one of the last unconsolidated sub-GHz spectrum that could easily be integrated into 5G networks, making it an attractive acquisition target for wireless and satellite companies, Oppenheimer said in a note Thursday.

Analysts said they believe approval of NextNav's proposal is "imminent." If that happens, NextNav would gain an additional one megahertz of spectrum, giving it a contiguous 15 MHz in the lower 900 MHz band, according to the note.

This spectrum could end up being worth "substantially" more than the current estimate, especially depending on Federal Communications Commission rules around power and coverage, the brokerage said.

An approval would also remove geographic limits, service restrictions, and interference rules, turning a constrained asset into a clean 5G-ready spectrum block, the analysts said, adding that "for geopolitical reasons we believe the FCC is supportive of getting this spectrum deployed and having a GPS alternative."

Analysts said that, because of this, several potential buyers could be interested, including major wireless and satellite companies like AT&T (T), Verizon (VZ), or even SpaceX, with AT&T being the "most logical fit."

Oppenheimer upgraded NextNav to outperform from perform, with a $25 price target.

Price: $20.51, Change: $+3.54, Percent Change: +20.86%

Related Articles

Wire

Savara Says FDA Extended Review Period for Molgramostim Inhalation Solution Application

Savara (SVRA) said late Wednesday the US Food and Drug Administration has extended the review period for molgramostim biologics license application in autoimmune pulmonary alveolar proteinosis, a rare lung disease, by three months.The new prescription drug user fee act target action date for the inhalation solution is Nov. 22, the company said.The FDA did not cite any efficacy, safety, or manufacturing concerns, the company said, adding that the FDA determined that the responses to recent information requests represented a significant amendment to the application.

$SVRA
Wire

Euroseas Extends EM Kea Charter for Three Years at Higher Daily Rate

Euroseas (ESEA) extended a charter contract for its feeder containership EM Kea by three years at a gross daily rate of $30,000.The charter is set to begin on July 14 and reflects nearly a 60% increase over the vessel's current rate, the company said Wednesday in a statement.Euroseas expects the charter to generate about $22.5 million in EBITDA over the minimum contracted period.The company's shares fell 2% in after-hours trading.

$ESEA
Wire

Voyager Wins NASA Order for Seventh Private Astronaut Mission to International Space Station

Voyager Technologies (VOYG) said late Wednesday it has signed an order with National Aeronautics and Space Administration for the seventh private astronaut mission to the International Space Station, with a launch planned no earlier than 2028.The mission, dubbed VOYG-1, supports NASA's strategy to shift low-Earth orbit operations to the private sector by enabling commercial partners to deliver human spaceflight services, the company said.

$VOYG